With the two active components, sitagliptin and metformin, Janumet has a comprehensive mechanism of action that targets all three key defects of T2DM for improved glycemic control: diminished insulin ...
Sitagliptin, metformin (as HCl) ext-rel; 50mg/500mg, 50mg/1000mg, 100mg/1000mg; tabs. Individualize. Swallow whole. Take once daily with a meal, preferably in the evening. Not currently treated with ...
Merck announced that the FDA has approved Janumet XR (sitagliptin/metformin HCl extended-release tablets) for the treatment of type 2 diabetes. Janumet XR is indicated as an adjunct to diet and ...
Lupin has received tentative approval from the Food and Drug Administration for sitagliptin and metformin hydrochloride tablets, 50 mg/500 mg and 50 mg/1000 mg, which is a generic of Merck Sharp & ...
Janumet is indicated in combination with a sulphonylurea i. Janumet is also indicated as add-on to insulin i. The dose of antihyperglycaemic therapy with Janumet should be individualised on the basis ...
As a new class of OADs, DPP-4 inhibitors have many important advantages over other currently available antidiabetic drugs. Compared with currently available insulin secretagogues, DPP-4 inhibitors, by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results